190 related articles for article (PubMed ID: 34580712)
1. Pharmacological or genetic inhibition of hypoxia signaling attenuates oncogenic RAS-induced cancer phenotypes.
Zhu JY; Huang X; Fu Y; Wang Y; Zheng P; Liu Y; Han Z
Dis Model Mech; 2022 Feb; 15(2):. PubMed ID: 34580712
[TBL] [Abstract][Full Text] [Related]
2. HIF-1α inhibitor echinomycin reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect.
Yao Y; Wang L; Zhou J; Zhang X
J Transl Med; 2017 Feb; 15(1):28. PubMed ID: 28183349
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic targeting of TP53-mutated acute myeloid leukemia by inhibiting HIF-1α with echinomycin.
Wang Y; Liu Y; Bailey C; Zhang H; He M; Sun D; Zhang P; Parkin B; Baer MR; Zheng P; Malek SN; Liu Y
Oncogene; 2020 Apr; 39(14):3015-3027. PubMed ID: 32060420
[TBL] [Abstract][Full Text] [Related]
4. The HIF1α-PDGFD-PDGFRα axis controls glioblastoma growth at normoxia/mild-hypoxia and confers sensitivity to targeted therapy by echinomycin.
Peng G; Wang Y; Ge P; Bailey C; Zhang P; Zhang D; Meng Z; Qi C; Chen Q; Chen J; Niu J; Zheng P; Liu Y; Liu Y
J Exp Clin Cancer Res; 2021 Sep; 40(1):278. PubMed ID: 34470658
[TBL] [Abstract][Full Text] [Related]
5. Oncogenic K-ras in mouse models of myeloproliferative disease and acute myeloid leukemia.
Chan IT; Gilliland DG
Cell Cycle; 2004 May; 3(5):536-7. PubMed ID: 15020845
[TBL] [Abstract][Full Text] [Related]
6. Echinomycin protects mice against relapsed acute myeloid leukemia without adverse effect on hematopoietic stem cells.
Wang Y; Liu Y; Tang F; Bernot KM; Schore R; Marcucci G; Caligiuri MA; Zheng P; Liu Y
Blood; 2014 Aug; 124(7):1127-35. PubMed ID: 24994068
[TBL] [Abstract][Full Text] [Related]
7. Hematopoiesis and RAS-driven myeloid leukemia differentially require PI3K isoform p110α.
Gritsman K; Yuzugullu H; Von T; Yan H; Clayton L; Fritsch C; Maira SM; Hollingworth G; Choi C; Khandan T; Paktinat M; Okabe RO; Roberts TM; Zhao JJ
J Clin Invest; 2014 Apr; 124(4):1794-809. PubMed ID: 24569456
[TBL] [Abstract][Full Text] [Related]
8. Loss of Dnmt3a and endogenous Kras(G12D/+) cooperate to regulate hematopoietic stem and progenitor cell functions in leukemogenesis.
Chang YI; You X; Kong G; Ranheim EA; Wang J; Du J; Liu Y; Zhou Y; Ryu MJ; Zhang J
Leukemia; 2015 Sep; 29(9):1847-56. PubMed ID: 25801914
[TBL] [Abstract][Full Text] [Related]
9. Nf1 deficiency cooperates with oncogenic K-RAS to induce acute myeloid leukemia in mice.
Cutts BA; Sjogren AK; Andersson KM; Wahlstrom AM; Karlsson C; Swolin B; Bergo MO
Blood; 2009 Oct; 114(17):3629-32. PubMed ID: 19710506
[TBL] [Abstract][Full Text] [Related]
10. Ras oncogene-independent activation of RALB signaling is a targetable mechanism of escape from NRAS(V12) oncogene addiction in acute myeloid leukemia.
Pomeroy EJ; Lee LA; Lee RDW; Schirm DK; Temiz NA; Ma J; Gruber TA; Diaz-Flores E; Moriarity BS; Downing JR; Shannon KM; Largaespada DA; Eckfeldt CE
Oncogene; 2017 Jun; 36(23):3263-3273. PubMed ID: 27991934
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of autophagy with chloroquine is effective in melanoma.
Egger ME; Huang JS; Yin W; McMasters KM; McNally LR
J Surg Res; 2013 Sep; 184(1):274-81. PubMed ID: 23706562
[TBL] [Abstract][Full Text] [Related]
12. Effects of the hypoxia-inducible factor-1 inhibitor echinomycin on vascular endothelial growth factor production and apoptosis in human ectopic endometriotic stromal cells.
Tsuzuki T; Okada H; Shindoh H; Shimoi K; Nishigaki A; Kanzaki H
Gynecol Endocrinol; 2016; 32(4):323-8. PubMed ID: 26654708
[TBL] [Abstract][Full Text] [Related]
13. Oncogenic NRAS rapidly and efficiently induces CMML- and AML-like diseases in mice.
Parikh C; Subrahmanyam R; Ren R
Blood; 2006 Oct; 108(7):2349-57. PubMed ID: 16763213
[TBL] [Abstract][Full Text] [Related]
14. Effects of the HIF1 inhibitor, echinomycin, on growth and NOTCH signalling in leukaemia cells.
Yonekura S; Itoh M; Okuhashi Y; Takahashi Y; Ono A; Nara N; Tohda S
Anticancer Res; 2013 Aug; 33(8):3099-103. PubMed ID: 23898065
[TBL] [Abstract][Full Text] [Related]
15. Oncogenic K-ras cooperates with PML-RAR alpha to induce an acute promyelocytic leukemia-like disease.
Chan IT; Kutok JL; Williams IR; Cohen S; Moore S; Shigematsu H; Ley TJ; Akashi K; Le Beau MM; Gilliland DG
Blood; 2006 Sep; 108(5):1708-15. PubMed ID: 16675706
[TBL] [Abstract][Full Text] [Related]
16. RALB provides critical survival signals downstream of Ras in acute myeloid leukemia.
Eckfeldt CE; Pomeroy EJ; Lee RD; Hazen KS; Lee LA; Moriarity BS; Largaespada DA
Oncotarget; 2016 Oct; 7(40):65147-65156. PubMed ID: 27556501
[TBL] [Abstract][Full Text] [Related]
17. High-throughput sequencing screen reveals novel, transforming RAS mutations in myeloid leukemia patients.
Tyner JW; Erickson H; Deininger MW; Willis SG; Eide CA; Levine RL; Heinrich MC; Gattermann N; Gilliland DG; Druker BJ; Loriaux MM
Blood; 2009 Feb; 113(8):1749-55. PubMed ID: 19075190
[TBL] [Abstract][Full Text] [Related]
18. Oncogenic RAS enables DNA damage- and p53-dependent differentiation of acute myeloid leukemia cells in response to chemotherapy.
Meyer M; Rübsamen D; Slany R; Illmer T; Stabla K; Roth P; Stiewe T; Eilers M; Neubauer A
PLoS One; 2009 Nov; 4(11):e7768. PubMed ID: 19890398
[TBL] [Abstract][Full Text] [Related]
19. Echinomycin mitigates ocular angiogenesis by transcriptional inhibition of the hypoxia-inducible factor-1.
Plastino F; Santana-Garrido Á; Pesce NA; Aronsson M; Lardner E; Mate A; Kvanta A; Vázquez CM; André H
Exp Eye Res; 2021 May; 206():108518. PubMed ID: 33639134
[TBL] [Abstract][Full Text] [Related]
20. Targeting Ras signaling in AML: RALB is a small GTPase with big potential.
Pomeroy EJ; Eckfeldt CE
Small GTPases; 2020 Jan; 11(1):39-44. PubMed ID: 28682649
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
